NEWS RELEASE - REGULATED INFORMATION
22 November 2021, 11:00p.m. CET
MDxHealthShareholder Transparency Declarations
IRVINE, CA, and HERSTAL, BELGIUM - 22 November 2021 - MDxHealthSA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notifications.
MDxHealth was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed below the threshold of 3% of the outstanding shares and voting rights of MDxHealth on 16 November 2021. Notably, it follows from the notification that the previously reported shares of MDxHealth were held through Soleus Capital Master Fund, L.P., a limited partnership formed in the Cayman Islands. The notification also stated that the voting rights attached to the shares were exercised by the investment advisor Soleus Capital Management, L.P., a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Soleus Capital Management, L.P. is controlled by a sole general partner, Soleus GP, LLC, a Delaware limited liability company, and that Soleus GP, LLC is controlled by its sole member, Mr. Guy Levy.
MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 15% of the outstanding shares and voting rights of MDxHealth on 19 November 2021. Notably, it follows from the notification that an aggregate of 23,783,330 shares of MDxHealth, representing 15.25% of the 155,969,226 outstanding shares and voting rights of MDxHealth, is held through the following entities: 21 April Fund LP (5,824,498 shares), 21 April Fund LTD (15,042,162 shares), Hill Family Alternative Investments LLC (2,500,000 shares), and White Clover SA (416,670 shares) (the "Funds"). The notification also stated that the voting rights attached to the shares are exercised on behalf of the Funds by the investment adviser Bleichroeder LP, a Delaware limited partnership, at its discretion, in the absence of specific instructions, that Bleichroeder Holdings LLC, a Delaware limited liability company, is the general partner of Bleichroeder LP, that, as the general partner, Bleichroeder Holdings LLC holds control over voting rights of Bleichroeder LP, and that Bleichroeder Holdings LLC is not a controlled entity.
For further information, reference is made to the information published on MDxHealth's website).
Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
About MDxHealth
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic.comand follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealthand linkedin.com/company/mdxhealth.
| For more information: | |
| MDxHealth | |
| info@mdxhealth.com | |
Important information
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Attachment
- Transparency Press Release - Soleus and Bleichroeder (ENG) (https://ml-eu.globenewswire.com/Resource/Download/746b5e9f-8df0-4110-9a48-6f01386ed23c)
